Marksans Pharma Ltd.

Date: 23 November, 2026

BSE Limited
Corporate Relation Department
Phiroze Jeejeeboi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Sub.: USFDA inspection at Company's manufacturing facility in Verna, Goa, India

Dear Sirs,

This is to inform you that a current Good Manufacturing Practice (cGMP) inspection was conducted by the US FDA at the manufacturing facility of the Company located at L-82 & L-83, Verna Industrial Estate, Verna, Goa, India from 12 November 2026 to 20 November 2026.

On conclusion of the inspection, the Company was issued Form 483 with 6 observations. All Observations are procedural in nature. There is no observation related to data integrity or repeated observation.

The Company will work closely with the US FDA to address these observations comprehensively within the stipulated timeline and does not anticipate any impact on the new pipeline or commercial supplies from this site.

We will keep the exchanges informed about further updates in this matter.

Please take the above information on record.

Yours faithfully,
For **Marksans Pharma Limited**

H PANIGRAHI
Digitally signed by H PANIGRAHI
Date: 2026.11.23 08:57:15 +05'30'

Harshavardhan Panigrahi
Company Secretary

About Marksans Pharma

Marksans Pharma Ltd. (www.marksanspharma.com) headquartered in Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets. The Company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The Company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological, and Anti-allergies. The Company is marketing these products globally.